FDA Grants Pediatric Exclusivity For RISPERDAL(R)

... The U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for RISPERDAL(R) (risperidone), based on studies conducted in bipolar 1 disorder and schizophrenia. The patent is set to expire in December 2007, however, this grant will extend the period of exclusivity on risperidone through June 2008. RISPERDAL is approved in the U.S. [click link for full article] ...